Since its identification in the early 1980s,
People infected with HIV can live long, fulfilling lives with the diagnostics and treatments we have today. The challenge is ensuring that HIV positive people receive the help they need. In the countries hardest hit by the disease, access to the few healthcare centres that can diagnose, treat, and follow up HIV patient care has been extremely limited. Since 2002 and 2003, respectively, both the Global Fund and the United States President's Emergency Plan For AIDS Relief (PEPFAR), have invested heavily in providing the funds to supply quality testing and treatments to the people in need, along with building up the infrastructure needed.
To enable equitable access to HIV testing in resource-limited settings, and to support the UNAIDs 2020 (now 2030) targets, Roche created the
For example, we have developed a
The Global Access Program for HIV testing has seen a four-fold increase in tests run since launch. It is estimated that in 2021, over 8 million people in Africa used our viral load testing to manage their HIV infection and to date over 11 million babies have been tested for HIV with Roche tests, giving more children the chance to live a healthy life.
In addition, from 2015 to 2021 we have been able to train over 8300 laboratory professionals, covering over 100 training courses and workshops, across 18 countries, through the Roche Scientific Campus in South Africa.
In 2019, Roche expanded the
In 2021, molecular testing for detecting SARS-COV-2 was added to help countries manage their COVID-19 response. Many countries, especially those across Africa have been enabled to be better equipped to respond to COVID-19 thanks to decades of investments for health system strengthening and HIV/AIDS programs. However, COVID-19 has also placed a tremendous strain on critical health services including the HIV/AIDS programs putting lives at risk. We will continue to support these global health investments and emphasise the importance of diagnostic testing in reducing the spread of COVID-19 and supporting disease management in order to end AIDS by 2030.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.